Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arcturus Therapeutics ( (ARCT) ) has issued an update.
On August 29, 2025, Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., announced the approval in Japan for KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This vaccine targets the SARS-CoV-2 Omicron sub lineage JN.1 variant XEC and has shown efficacy against several other variants in non-clinical studies. The vaccine is supplied as a two-dose vial and distribution is set to begin in late September 2025. This development follows a distribution agreement with CSL Seqirus for the Japanese market, potentially strengthening the company’s position in the vaccine industry.
The most recent analyst rating on (ARCT) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.
Spark’s Take on ARCT Stock
According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.
Arcturus Therapeutics’ overall stock score is primarily influenced by its financial challenges, including declining revenues and negative cash flow. However, positive technical indicators and promising clinical progress provide some optimism. The company’s valuation remains a concern due to ongoing losses, but strategic developments and shareholder support offer potential for future growth.
To see Spark’s full report on ARCT stock, click here.
More about Arcturus Therapeutics
Average Trading Volume: 554,093
Technical Sentiment Signal: Hold
Current Market Cap: $469.8M
Learn more about ARCT stock on TipRanks’ Stock Analysis page.